THC.CSE THCBF – OTC TFHD.F
Vancouver, BC – (November 10, 2022) Due to high demand for its Kiss beverages, THC BioMed Intl Ltd. (“THC BioMed” or the “Company”) is automating its beverage production line. The equipment has been ordered from the U.S. and is scheduled to arrive in the next few weeks.
“Our THC Kiss Shots are bestsellers on both the Ontario and BC Cannabis Stores websites,” said John Miller, CEO of THC BioMed. “Since we produce and package everything in-house, automating our production line will help us meet current demand and ensure that we are prepared to meet increasing demand.”
THC BioMed is also investing in legal cannabis opportunities in Asia. It has made minimal investments to date but is working to develop further investment opportunities.
THC BioMed is one of Canada’s oldest active licensed cannabis companies. It was first licensed to deal with cannabis in 2013 under a Health Canada Section 56 exemption under the Controlled Drugs and Substances Act and has been a Licensed Producer under the current regime since 2016. Its product focus is on high-quality, high-potency beverages and edibles.
THC BioMed is a Cannabis Act Licensed Producer of medical and recreational cannabis. It is licensed to cultivate and sell dried, extract, edible and topical cannabis. The Company is on the leading edge of scientific research and the development of products and services in the medical and recreational cannabis industry. Management believes THC BioMed is well-positioned to be in the forefront of this industry.
President and CEO:
THC Biomed Intl Ltd.